Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163


EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.

Gao SB, Zheng QF, Xu B, Pan CB, Li KL, Zhao Y, Zheng QL, Lin X, Xue LX, Jin GH.

Mol Cancer Res. 2014 Oct;12(10):1388-97. doi: 10.1158/1541-7786.MCR-14-0034.


The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.

Gao SB, Xu B, Ding LH, Zheng QL, Zhang L, Zheng QF, Li SH, Feng ZJ, Wei J, Yin ZY, Hua X, Jin GH.

J Hepatol. 2014 Oct;61(4):832-9. doi: 10.1016/j.jhep.2014.05.015.


Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.

Tsang DP, Wu WK, Kang W, Lee YY, Wu F, Yu Z, Xiong L, Chan AW, Tong JH, Yang W, Li MS, Lau SS, Li X, Lee SD, Yang Y, Lai PB, Yu DY, Xu G, Lo KW, Chan MT, Wang H, Lee TL, Yu J, Wong N, Yip KY, To KF, Cheng AS.

J Pathol. 2016 Apr;238(5):651-64. doi: 10.1002/path.4688.


Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.

Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM.

Hepatology. 2012 Aug;56(2):622-31. doi: 10.1002/hep.25679.


Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.

Xie CR, Li Z, Sun HG, Wang FQ, Sun Y, Zhao WX, Zhang S, Zhao WX, Wang XM, Yin ZY.

Oncotarget. 2015 Dec 1;6(38):40940-52. doi: 10.18632/oncotarget.5724.


CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.

Li CP, Cai MY, Jiang LJ, Mai SJ, Chen JW, Wang FW, Liao YJ, Chen WH, Jin XH, Pei XQ, Guan XY, Zeng MS, Xie D.

Carcinogenesis. 2016 Jun;37(6):557-66. doi: 10.1093/carcin/bgw036.


A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.

Feng H, Yu Z, Tian Y, Lee YY, Li MS, Go MY, Cheung YS, Lai PB, Chan AM, To KF, Chan HL, Sung JJ, Cheng AS.

J Hepatol. 2015 May;62(5):1100-11. doi: 10.1016/j.jhep.2014.11.040.


FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.

Du J, Li L, Ou Z, Kong C, Zhang Y, Dong Z, Zhu S, Jiang H, Shao Z, Huang B, Lu J.

Breast Cancer Res Treat. 2012 Jan;131(1):65-73. doi: 10.1007/s10549-011-1396-3. Erratum in: Breast Cancer Res Treat. 2016 Apr;156(3):609-10.


EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.

Cancer Res. 2011 Jun 1;71(11):4028-39. doi: 10.1158/0008-5472.CAN-10-3342.


MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.

Xia H, Ooi LL, Hui KM.

PLoS One. 2012;7(9):e44206. doi: 10.1371/journal.pone.0044206. Erratum in: PLoS One. 2012;7(9). doi:10.1371/annotation/1be2a62e-45a1-4c13-9a8d-f265005a21e0.


EZH2-induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in ovarian cancer.

Fu Y, Chen J, Pang B, Li C, Zhao J, Shen K.

Cell Biochem Biophys. 2015 Jan;71(1):105-12. doi: 10.1007/s12013-014-0168-1.


The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.

Kogure M, Takawa M, Saloura V, Sone K, Piao L, Ueda K, Ibrahim R, Tsunoda T, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R.

Neoplasia. 2013 Nov;15(11):1251-61.


Histone-modifying genes as biomarkers in hepatocellular carcinoma.

Hung SY, Lin HH, Yeh KT, Chang JG.

Int J Clin Exp Pathol. 2014 Apr 15;7(5):2496-507.


Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells.

French BA, Oliva J, Bardag-Gorce F, Li J, Zhong J, Buslon V, French SW.

Exp Mol Pathol. 2012 Jun;92(3):318-26. doi: 10.1016/j.yexmp.2012.02.003.


The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.

Turgeon N, Blais M, Delabre JF, Asselin C.

J Cell Biochem. 2013 May;114(5):1203-15. doi: 10.1002/jcb.24463.


H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.

Chen S, Chen J, Zhan Q, Zhu Y, Chen H, Deng X, Hou Z, Shen B, Chen Y, Peng C.

Oncotarget. 2014 Nov 15;5(21):10421-33.


P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression.

Zhang EB, Yin DD, Sun M, Kong R, Liu XH, You LH, Han L, Xia R, Wang KM, Yang JS, De W, Shu YQ, Wang ZX.

Cell Death Dis. 2014 May 22;5:e1243. doi: 10.1038/cddis.2014.201.


Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.

Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D.

Mol Cell Biol. 2008 Apr;28(8):2718-31. doi: 10.1128/MCB.02017-07.


MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.

Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR.

J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028.


EZH2 methyltransferase and H3K27 methylation in breast cancer.

Yoo KH, Hennighausen L.

Int J Biol Sci. 2012;8(1):59-65. Review.

Items per page

Supplemental Content

Support Center